WO2023185597A1 - Intermédiaire de letermovir et son procédé de préparation - Google Patents
Intermédiaire de letermovir et son procédé de préparation Download PDFInfo
- Publication number
- WO2023185597A1 WO2023185597A1 PCT/CN2023/083173 CN2023083173W WO2023185597A1 WO 2023185597 A1 WO2023185597 A1 WO 2023185597A1 CN 2023083173 W CN2023083173 W CN 2023083173W WO 2023185597 A1 WO2023185597 A1 WO 2023185597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetate
- piperazin
- methoxyphenyl
- fluoro
- methoxy
- Prior art date
Links
- FWYSMLBETOMXAG-QHCPKHFHSA-N letermovir Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N([C@@H](CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-QHCPKHFHSA-N 0.000 title claims abstract description 31
- 229950010668 letermovir Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000012442 inert solvent Substances 0.000 claims abstract description 22
- 150000003892 tartrate salts Chemical class 0.000 claims abstract description 10
- DDWYVVLPVLTZIN-UHFFFAOYSA-N methyl 2-[8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate Chemical compound N=1C2=C(F)C=CC=C2C(CC(=O)OC)N(C=2C(=CC=C(C=2)C(F)(F)F)OC)C=1N(CC1)CCN1C1=CC=CC(OC)=C1 DDWYVVLPVLTZIN-UHFFFAOYSA-N 0.000 claims abstract description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 239000000543 intermediate Substances 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 13
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 229940095064 tartrate Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 8
- 229940011051 isopropyl acetate Drugs 0.000 claims description 8
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- DDWYVVLPVLTZIN-DEOSSOPVSA-N methyl 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate Chemical compound C=1C(C(F)(F)F)=CC=C(OC)C=1N([C@H](C1=CC=CC(F)=C1N=1)CC(=O)OC)C=1N(CC1)CCN1C1=CC=CC(OC)=C1 DDWYVVLPVLTZIN-DEOSSOPVSA-N 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 239000003759 ester based solvent Substances 0.000 claims description 3
- 239000004210 ether based solvent Substances 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims 1
- 238000009776 industrial production Methods 0.000 abstract description 4
- -1 (S)-methyl {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetate tartrate salt Chemical compound 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VWELDTSVCPBACW-UHFFFAOYSA-N CC(=O)OCC1C2=C(C(=CC=C2)F)N=C(N1C3=C(C=CC(=C3)C(F)(F)F)OC)N4CCN(CC4)C5=CC(=CC=C5)OC Chemical compound CC(=O)OCC1C2=C(C(=CC=C2)F)N=C(N1C3=C(C=CC(=C3)C(F)(F)F)OC)N4CCN(CC4)C5=CC(=CC=C5)OC VWELDTSVCPBACW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- ORBOVPDSXOKTQB-GDGVXITASA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid;methyl 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1.C=1C(C(F)(F)F)=CC=C(OC)C=1N([C@H](C1=CC=CC(F)=C1N=1)CC(=O)OC)C=1N(CC1)CCN1C1=CC=CC(OC)=C1 ORBOVPDSXOKTQB-GDGVXITASA-N 0.000 description 1
- FWYSMLBETOMXAG-UHFFFAOYSA-N 2-[8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N(C(CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-UHFFFAOYSA-N 0.000 description 1
- WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Definitions
- the invention belongs to the field of drug synthesis. Specifically, the invention relates to a letermovir intermediate and a preparation method thereof.
- Letermovir is mainly used to prevent CMV infection in adult patients who are seropositive for cytomegalovirus after allogeneic hematopoietic stem cell transplantation.
- Route 1, Route 2, and Route 4 all require (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]-succinic acid to resolve ⁇ 8-fluoro-2-[4- (3-Methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4- base ⁇ methyl acetate to obtain (S)- ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-( Trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetate methyl ester (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy] -succinate, which is subsequently freed and hydrolyzed to give letermovir.
- the main defect of the above process is: ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl )Phenyl]-3,4-dihydroquinazolin-4-yl ⁇ enantiomers of methyl acetate.
- the salt obtained after separation is only 98.0% e.e., with a yield of 89%. It needs to be crystallized again to obtain 99.9% e.e. Product, yield 80%, long cycle.
- the enantiomeric content in raw materials containing chiral centers is a very critical quality indicator, and usually the enantiomeric content needs to be strictly controlled below 0.15%.
- multiple recrystallization extractions are required. High optical purity will inevitably bring disadvantages such as extended production cycle, increase of three wastes, and low yield.
- the object of the present invention is to provide a letermovir intermediate with high yield and high optical purity and a preparation method thereof.
- a first aspect of the invention provides a letermovir intermediate (S)- ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[ 2-Methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetic acid methyl ester chiral modified salt, the intermediate is (S)- ⁇ 8-Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3, D-(+)-dibenzoyl tartrate of methyl 4-dihydroquinazolin-4-yl ⁇ acetate,
- the second aspect of the present invention provides a method for preparing the intermediate described in the first aspect of the present invention.
- the method includes the steps of: in an inert solvent, ⁇ 8-fluoro-2-[4-(3- Methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetic acid
- the methyl ester is crystallized with chiral modified tartaric acid to obtain (S)- ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy Tartrate of methyl-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetate;
- the chiral modified tartaric acid is selected from the following group: D-(+)-dibenzoyltartaric acid, D-(+)-di-p-methoxybenzoyltartaric acid.
- the method further includes post-processing.
- the post-processing includes: filtration, washing, extraction and drying.
- the chirally modified tartaric acid is D-(+)-di-p-methoxybenzoyltartaric acid.
- the inert solvent is selected from the following group: C1-C10 ester solvents, C6-C10 aromatic hydrocarbon solvents, C2-C6 ether solvents, or combinations thereof.
- the solvent is selected from the following group: ethyl acetate, methyl acetate, isopropyl acetate, acetic acid Tert-butyl ester, butyl acetate, toluene, tetrahydrofuran, methyl tert-butyl ether, diisopropyl ether, or combinations thereof.
- the volume (v/v) ratio of fluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetate to inert solvent is 1:3-10.
- the ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(tri) is 1:1.0-1.5.
- the crystallization temperature is 0-80°C, preferably 20-40°C.
- the crystallization process includes: stirring.
- the crystallization time is 2-15h, preferably 5-8h.
- the method further includes: filtering the reaction mixture after the reaction is completed, washing the filter cake with an inert solvent at 0-10°C, then adding MTBE, and adding alkali and water for cleaning.
- the base is NaHCO 3 , Na 2 HPO 4 , or a combination thereof.
- MTBE can also be replaced with a solvent selected from the following group: toluene, ethyl acetate, isopropyl acetate, or a combination thereof.
- a third aspect of the present invention provides a method for preparing letermovir, which method includes:
- the step (2) includes: dissolving the chiral modified salt in a first inert solvent, and then adding a base, water and a second inert solvent to react; preferably, the The first inert solvent is methyl tert-butyl ether; the second inert solvent is methanol;
- the reaction After the reaction is completed, add water and a third inert solvent, and separate the aqueous phase; preferably, the third inert solvent is methyl tert-butyl ether;
- the first inert solvent is selected from the following group: methyl tert-butyl ether, toluene, isopropyl acetate, or a combination thereof; preferably methyl tert-butyl ether.
- the second inert solvent is selected from the following group: methyl tert-butyl ether, toluene, isopropyl acetate, or a combination thereof; preferably, it is methanol.
- the third inert solvent is selected from the following group: methanol, ethanol, isopropyl alcohol, or a combination thereof.
- the base is KOH, NaOH, or a combination thereof.
- reaction time is 4-12h, preferably 6-8h.
- the reaction temperature is 20-80°C, preferably 40-60°C.
- the present invention developed a novel letermovir intermediate and its preparation method for the first time.
- the method of the present invention has the characteristics of simple operation, high yield and high product purity. On this basis, the present invention was completed.
- room temperature or "normal temperature” refers to a temperature of 4-40°C, preferably 25 ⁇ 5°C.
- each substance in the reaction system of each reaction step, can independently participate in the reaction in any suitable ratio, such as 1: (0.1-10), 1: (0.2- 5), 1: (0.5-2), 1: (0.8-1.5) or 1: (1.0-1.2).
- Letermovir intermediate of the present invention has a structure selected from the following group:
- the present invention provides a new preparation method of letermovir intermediate, which requires only one crystallization, has a short production cycle, and obtains letermovir intermediate with high e.e. value.
- the letermovir intermediate of the present invention can be prepared by the following method.
- the conditions of the method such as reactants, solvents, bases, acids, amounts of compounds used, reaction temperature, reaction time required, etc. are not limited to the following explanations.
- the preparation method of the letermovir intermediate is as follows:
- the proportion of reaction materials is not particularly limited, for example, ⁇ 8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy
- the molar ratio of methyl-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl ⁇ acetate and chiral modified tartaric acid is 1:1.0-1.5; ⁇ 8- Fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-di
- the volume (v/v) ratio of hydroquinazolin-4-yl ⁇ acetate to inert solvent is 1:3-10.
- the inert solvent, reaction time, reaction crystallization temperature, etc. can be selected according to specific circumstances.
- the inert solvent is selected from the following group: C1-C10 ester solvents, C6-C10 aromatic hydrocarbon solvents, C2-C6 ether solvents, or combinations thereof; preferably ethyl acetate, methyl acetate, isopropyl acetate, tertiary acetate Butyl ester, butyl acetate, toluene, tetrahydrofuran, methyl tert-butyl ether, diisopropyl ether, or combinations thereof.
- the reaction temperature is 0-80°C, preferably 20-40°C; the crystallization time is 2-15h, preferably 5-8h.
- the advantages of the present invention mainly include:
- the preparation method of the present invention requires only one crystallization to make the e.e. value of the previous step intermediate of letermovir API reach more than 99.9%, fully ensuring the optical purity of letermovir API.
- the preparation method of the present invention has a short production cycle and high yield, and is suitable for industrial production.
- the obtained filter cake was added to MTBE (80 mL), and Na 2 HPO 4 (12.10 g) and water (80 mL) were added. The mixture was stirred at 20-30°C for 1 hour, separated into layers, and the organic layer was washed once with water (40 mL). The organic layer was concentrated to dryness, and the obtained solid was vacuum dried at 50°C for 18 hours. The total amount of solid obtained was 17.48g (99.93%ee, yield 95.0%).
- the obtained filter cake was added to MTBE (80 mL), and Na 2 HPO 4 (12.10 g) and water (80 mL) were added. The mixture was stirred at 20-30°C for 1 hour, separated into layers, and the organic layer was washed once with water (40 mL). The organic layer was concentrated to dryness, and the obtained solid was vacuum dried at 50°C for 18 hours. The total amount of solid obtained was 17.57g (99.94%ee, yield 95.5%)
- the single impurity content is required to be less than 0.1%.
- secondary crystallization is required to increase the ee value of the product to 99.90% (i.e., the single impurity qualifying standard).
- the method of the present invention one crystallization can make the ee value of the product far exceed the qualified standard, so it is very suitable for industrial production.
- the preparation method of the letermovir intermediate of the present invention requires fewer crystallizations, requires only one crystallization, and has low three-waste treatment costs; in addition, the preparation method of the present invention has a short production cycle, but the product purity is high, and is suitable for industrial production.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un intermédiaire de letermovir et son procédé de préparation. Plus particulièrement, le procédé comprend l'étape consistant à : cristalliser de l'acétate de {8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]-3,4-dihydroquinazolin-4-yl} de méthyle avec de l'acide tartrique modifié chiral dans un solvant inerte pour obtenir un sel de tartrate d'acétate de (S)-méthyl {8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]-3,4-dihydroquinazolin-4-yl}. Le procédé selon la présente invention présente les caractéristiques d'un mode opératoire simple, d'un rendement élevé, d'une pureté de produit élevée, d'une aptitude à la production industrielle, etc
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210371221 | 2022-04-01 | ||
CN202210371221.4 | 2022-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023185597A1 true WO2023185597A1 (fr) | 2023-10-05 |
Family
ID=88199228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/083173 WO2023185597A1 (fr) | 2022-04-01 | 2023-03-22 | Intermédiaire de letermovir et son procédé de préparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023185597A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784390A (zh) * | 2003-05-02 | 2006-06-07 | 拜耳医药保健股份公司 | 具有抗病毒性能的取代二氢喹唑啉 |
CN101863843A (zh) * | 2005-06-15 | 2010-10-20 | 艾库里斯有限及两合公司 | 制备二氢喹唑啉的方法 |
WO2015088931A1 (fr) * | 2013-12-12 | 2015-06-18 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés quinazoline substitués |
WO2017091453A1 (fr) * | 2015-11-24 | 2017-06-01 | Merck Sharp & Dohme Corp. | Nouveaux procédés de production de composés de quinazoline substitués à l'aide de catalyseurs de liaison hydrogène |
WO2022018625A1 (fr) * | 2020-07-21 | 2022-01-27 | Olon S.P.A. | Procédé de préparation d'un intermédiaire utilisé dans la synthèse du létermovir |
-
2023
- 2023-03-22 WO PCT/CN2023/083173 patent/WO2023185597A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784390A (zh) * | 2003-05-02 | 2006-06-07 | 拜耳医药保健股份公司 | 具有抗病毒性能的取代二氢喹唑啉 |
CN101863843A (zh) * | 2005-06-15 | 2010-10-20 | 艾库里斯有限及两合公司 | 制备二氢喹唑啉的方法 |
WO2015088931A1 (fr) * | 2013-12-12 | 2015-06-18 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés quinazoline substitués |
WO2017091453A1 (fr) * | 2015-11-24 | 2017-06-01 | Merck Sharp & Dohme Corp. | Nouveaux procédés de production de composés de quinazoline substitués à l'aide de catalyseurs de liaison hydrogène |
WO2022018625A1 (fr) * | 2020-07-21 | 2022-01-27 | Olon S.P.A. | Procédé de préparation d'un intermédiaire utilisé dans la synthèse du létermovir |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106256824A (zh) | 一种高纯度德拉沙星葡甲胺盐的制备方法 | |
CN110724100B (zh) | 一种苯磺顺阿曲库铵中间体的制备方法 | |
CN113214223B (zh) | 一种富马酸伏诺拉生杂质的制备方法 | |
AU2016232270A1 (en) | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | |
WO2023185597A1 (fr) | Intermédiaire de letermovir et son procédé de préparation | |
WO2012167413A1 (fr) | Procédé de préparation d'un composé de type clausenamide (-)- optiquement pur | |
CN104277053B (zh) | 一种头孢地嗪及其中间体头孢地嗪酸的制备方法 | |
CN111072633A (zh) | 一种埃索美拉唑镁三水合物的制备方法 | |
CN115368318B (zh) | 一种伏硫西汀的合成方法及应用 | |
WO2021037022A1 (fr) | Procédé de préparation de 4-méthyl-5-alcoxy-oxazole | |
CN102382041B (zh) | 一种马来酸氨氯地平的制备方法 | |
CN101550107B (zh) | 一种替米沙坦的制备方法 | |
CN114085209B (zh) | 一种氯雷他定关键中间体的纯化方法 | |
CN104725259A (zh) | 左旋多巴中间体衍生物的制备方法 | |
CN110746371B (zh) | 制备阿瑞匹坦的中间体及其制备方法与应用 | |
CN115894311B (zh) | (2s,3r)-2-氨基-3-羟基-3-(4-(甲基磺酰基)苯基)丙酸乙酯的制备 | |
CN114507242B (zh) | 高光学纯度左氧氟沙星的制备方法 | |
CN114181078B (zh) | 一种3-羟基-2-萘甲酸苯酯的精制方法 | |
CN114213343B (zh) | 一种赛乐西帕中间体的制备及其纯化方法 | |
CN116731012A (zh) | 一种非奈利酮混旋体的制备方法 | |
CN102757414A (zh) | 艾司西酞普兰草酸盐的制备方法 | |
CN101434533A (zh) | 一种新型的索法酮制备方法 | |
CN116284019A (zh) | 一种医药中间体呋喃并[3,2-c]吡啶-4(5H)-酮衍生物的制备方法 | |
CN115215877A (zh) | 一种安纳拉唑的制备方法 | |
CN117756801A (zh) | 一种非奈利酮的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23777967 Country of ref document: EP Kind code of ref document: A1 |